Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.
Danson SJ, Johnson P, Ward TH, Dawson M, Denneny O, Dickinson G, Aarons L, Watson A, Jowle D, Cummings J, Robson L, Halbert G, Dive C, Ranson M. Danson SJ, et al. Among authors: ranson m. Ann Oncol. 2011 Jul;22(7):1653-1660. doi: 10.1093/annonc/mdq638. Epub 2011 Mar 4. Ann Oncol. 2011. PMID: 21378203 Free article. Clinical Trial.
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M. Dean E, et al. Among authors: ranson m. J Clin Oncol. 2009 Apr 1;27(10):1660-6. doi: 10.1200/JCO.2008.19.5677. Epub 2009 Feb 23. J Clin Oncol. 2009. PMID: 19237630 Clinical Trial.
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D, McMurry TB, Margison GP. Ranson M, et al. Clin Cancer Res. 2006 Mar 1;12(5):1577-84. doi: 10.1158/1078-0432.CCR-05-2198. Clin Cancer Res. 2006. PMID: 16533784 Clinical Trial.
DT-diaphorase: a target for new anticancer drugs.
Danson S, Ward TH, Butler J, Ranson M. Danson S, et al. Among authors: ranson m. Cancer Treat Rev. 2004 Aug;30(5):437-49. doi: 10.1016/j.ctrv.2004.01.002. Cancer Treat Rev. 2004. PMID: 15245776 Review.
IAPs as a target for anticancer therapy.
Danson S, Dean E, Dive C, Ranson M. Danson S, et al. Among authors: ranson m. Curr Cancer Drug Targets. 2007 Dec;7(8):785-94. doi: 10.2174/156800907783220471. Curr Cancer Drug Targets. 2007. PMID: 18220537 Review.
Optimisation of circulating biomarkers of cell death for routine clinical use.
Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C. Greystoke A, et al. Among authors: ranson m. Ann Oncol. 2008 May;19(5):990-5. doi: 10.1093/annonc/mdn014. Epub 2008 Feb 27. Ann Oncol. 2008. PMID: 18304966 Free article.
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JHM, Shapiro GI. Boss DS, et al. Among authors: ranson m. Ann Oncol. 2010 Apr;21(4):884-894. doi: 10.1093/annonc/mdp377. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825886 Free PMC article. Clinical Trial.
353 results